IP Verse

Dosing Regimen For Multiple Sclerosis

Patent No. EP3199172 (titled "Dosing Regimen For Multiple Sclerosis") was filed by Yeda Research on Aug 19, 2010. The application was issued on Jul 11, 2018.

Patent Summary

Reducing the frequency of subcutaneous glatiramer acetate injections from daily to three times a week for treating relapsing multiple sclerosis to improve tolerability without compromising efficacy. The lower frequency regimen is three injections over seven days with at least one day between each injection. This reduces post-injection reactions and improves patient compliance compared to daily injections.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ALVOGEN IPCOApr 11, 2019HAMM & WITTKOPP
G L PHARMAApr 11, 2019HAMM & WITTKOPP
SYNTHONApr 11, 2019HAMM & WITTKOPP
HEXALApr 10, 2019KIES
GENERICS UK TRADING MYLANMar 25, 2019GILL JENNINGS & EVERY

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3199172

YEDA RESEARCH
Application Number
EP17157735A
Filing Date
Aug 19, 2010
Status
Revoked
May 10, 2024
Publication Date
Jul 11, 2018
External Links
Slate, Register , Google Patents